Inexoplat develops immune-based therapies targeting the tumor microenvironment using exosome technology to enhance drug delivery and reduce toxicity. The company addresses the unmet medical needs in cancer treatment by providing patients with more effective and accessible therapeutic options that improve their quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to systemic toxicity and limited efficacy due to their inability to selectively target the tumor microenvironment. There is a need for therapies that can effectively deliver drugs to tumors while minimizing harm to healthy tissues.
Solution
Inexoplat is developing immune-based therapies that target the tumor microenvironment (TME) using exosome technology to enhance drug delivery and reduce toxicity. Their approach focuses on modulating the tumor microenvironment by targeting tumor-associated macrophages (TAMs). By engineering exosomes to deliver specific payloads, Inexoplat aims to reprogram the TME to support anti-tumor immunity. The company's technology seeks to improve the efficacy and accessibility of cancer treatments, offering patients more effective therapeutic options with an improved quality of life. Inexoplat leverages its expertise in process development and biological manufacturing to create novel cancer therapies.
Target Audience
Inexoplat's primary target audience includes cancer patients with unmet medical needs, as well as pharmaceutical companies and research institutions seeking innovative approaches to cancer treatment.
Features
- Exosome-based drug delivery platform for targeted therapy
- Focus on tumor microenvironment modulation, specifically targeting macrophages
- Development of immunotherapies to enhance anti-tumor immune responses
- Capability to identify and select target diseases with high unmet medical needs and large market potential
- Modality design to ensure target delivery, versatility, and low toxicity
- Expertise in biological agent development processes
- Proprietary technology for commercial-scale drug manufacturing